2-2021

Are Consortia Polymicrobial Urinary Tract Infections More Symptomatic Than Monomicrobial? Results From a Multi-Institutional Study

Annah Vollstedt
Beaumont Health Fellow

Dakun Wang

Natalie Luke

David Baunoch

Kirk J. Wojno
Beaumont Health

See next page for additional authors

Authors

Annah Vollstedt, Dakun Wang, Natalie Luke, David Baunoch, Kirk J. Wojno, Kevin Cline, Natalie Gaines, Howard Korman, S Mohammad Jafri, David Wenzler, Frank Burks, and Larry Sirls

image processing and atomic modeling, refinement, and validation, the structures were solved.
Results: Cryo-electron microscopy structures were solved for the three-subunit PapCDKFG complex at 5.8 Å resolution, and for the two-subunit PapCDKG complex at 3.8 and 7.2 Å resolution, respectively.
Conclusion: Our cryo-EM structures show processive steps in P pilus biogenesis, reveal differences between P and type 1 pili, and capture new conformational dynamics of the usher assembly machine. We present here the first structures of the activated PapC usher captured during the pilus assembly process. These structures pave the way for novel therapeutics designed against P pili and other virulence factors assembled by the CU pathway, which may provide alternatives to the use of antibiotics in the treatment of urinary tract infections and other infectious diseases.
Funding: F30AI112252 (GW); R01GM062987 (DT)

#BS23 | ARE CONSORTIA POLYMICROBIAL URINARY TRACT INFECTIONS MORE SYMPTOMATIC THAN MONOMICROBIAL? RESULTS FROM A MULTI-INSTITUTIONAL STUDY

Annah Vollstedt, MD[1], Dakun Wang, PhD[2], Natalie Luke, PhD[3], David Baunoch, PhD[3], Kirk Wojno, MD[4], Kevin Cline, MD[5], Laurence Belkoff, MD[6], Aaron Milbank, MD[7], Neil Sherman, MD[8], Rashel Haverkorn, MD[9], Natalie Gaines, MD[10], Laurence Yore, MD[11], Neal Shore, MD[12], Michael Opel, PhD[3], Howard Korman, MD[4], Shuguang Huang, PhD[2], Hannah Zhao, PhD[2], Miguel Penaradnda[13], Mohammad Jafri, MD[4], David Wenzler[4], Frank Burks, MD[4], Patrick Cacdac, MD[3], Larry Sirls, MD[4]
[1]Beaumont Hospital, Royal Oak, MI, [2]Stat4ward, Gibsonia, PA, [3]Pathnostics, Irvine, CA, [4]Comprehensive Urology, Royal Oak, MI, [5]Regional Urology, LL, Shreveport, LA, [6]Urologic Consultants of SE PA, Cynwyd, PA, [7]Minnesota Urology, Coon Rapids, MN, [8]Premier Urology. Edison, NJ, [9]Urology San Antonio, San Antonio, TX, [10]Amarillo Urology Associates, LLC, Amarillo, TX, [11]Advanced Urology of South Florida, Delray, FL, [12]Carolina Urologic Research Center, Myrtle Beach, SC, [13]Pathnostics, Irinve, CA

Presented By: Annah Vollstedt, MD

Introduction: Polymerase chain reaction (PCR) has been shown to be more sensitive in the detection of polymicrobial infections in patients with urinary tract infection (UTI). Bacterial consortia are non-random communities of microbes that may act synergistically to provide growth and survival advantages. We aim to investigate the relationship between bacteria detected by PCR, and the presence of consortia, with clinical findings in patients with symptomatic UTI.
Methods: We performed a retrospective analysis of 2493 UTI-symptomatic patients over the age of 60 from 37 geographically disparate urology clinics in the U.S. from July 2018 to February 2019. Clinical findings, including UA dipstick results and UTI symptoms, were recorded. Multiplex PCR (M-PCR) was performed to detect 24 different bacterial species in the urine specimens. A cutoff of 10 detections was used to distinguish a bacterial consortium from a random association of bacteria in a polymicrobial specimen. Summary statistics and Kruskal-Wallis test were used to compare the mean numbers of clinical findings across different number of bacterial species within a bacterial consortium.
Results: Bacteria were detected in 69% (1710/2493) of patients. Among these, monomicrobial infections were found in 40% (683/1710), and polymicrobial infections were found in 60% (1027/1710). Among the polymicrobial infections, consortia were identified in 433 specimens. Consortia polymicrobial urine specimens had more clinical findings than monomicrobial specimens, 2.84 vs. 2.66, respectively ($p=0.022$). The more bacteria detected within a consortium, the more clinical findings were reported ($p=0.026$), **Table 1.** Among consortia polymicrobial specimens, specimens containing Gram-negative bacteria were associated with a higher number of clinical findings compared to specimens without Gram-negative bacteria, 3.21 vs. 2.52, respectively ($p<0.0001$).
Conclusion: Consortia polymicrobial UTIs were associated with more clinical findings than monomicrobial infections. The number of clinical findings also increased with increasing numbers of bacteria within a consortium. The identification of a consortium within polymicrobial UTIs and the correlation of clinical findings may be important for understanding the treatment of polymicrobial UTIs.

Table 1. Mean number of clinical findings by number of bacteria detected

Bacterial content of urine specimen	Number of specimens	Mean number of clinic findings (standard deviation, range)
Monomicrobial	683	2.66 (1.25, 0-6)
Consortia polymicrobial	433	2.84 (1.25, 0-6)
2 bacteria within consortia	271	2.77 (128, 0-6)
3 bacteria within consortia	144	2.85 (1.15, 1-6)
4 bacteria within consortia	18	3.72 (1.41, 2-6)

Funding: Pathnostics

#BS24 | CONCORDANCE BETWEEN ANTIBIOTIC RESISTANCE GENES BY MULTIPLEX POLYMERASE CHAIN REACTION AND ANTIBIOTIC SUSCEPTIBILITY BY POOLED ANTIBIOTIC SENSITIVITY TESTING IN SYMPTOMATIC PATIENTS WITH URINARY TRACT INFECTION

Annah Vollstedt, MD[1], Dakun Wang, PhD[2], Natalie Luke, PhD[3], David Baunoch, PhD[3], Kirk Wojno, MD[4], Kevin Cline, MD[5], Laurence Belkoff, MD[6], Aaron Milbank, MD[7], Neil Sherman, MD[8], Rashel Haverkorn, MD[9], Natalie Gaines, MD[10], Laurence Yore, MD[11], Neal Shore, MD[12], Michael Opel, PhD[3], Howard Korman, MD[4], Shuguang Huang, PhD[2], Hannah Zhao, PhD[2], Miguel Penaranda[3], Mohammand Jafi, MD[4], David Wenzler[4], Frank Burks, MD[4], Patrick Cacdac, MD[3], Larry Sirls, MD[4]

[1]Beaumont Hospital, Royal Oak, MI, [2]Stat4ward, Gibsonia, PA, [3]Pathnostics, Irvine, CA, [4]Comprehensive Urology, Royal Oak, MI, [5]Regional Urology, LLC, Shreveport, LA, [6]Urologic Consultants of SE PA, Cynwyd, PA, [7]Minnesota Urology, Coon Rapids, MN, [8]Premier Urology, Edison, NJ, [9]Urology San Antonio, San Antonio, TX, [10]Amarillo Urology Associates, LLC, Amarillo, TX, [11]Advanced Urology of South Florida, Delray, FL, [12]Carolina Urologic Research Center, Myrtle Beach, SC

Presented By: Annah Vollstedt, MD

Introduction: Studies have shown many genes influence antibiotic resistance, and the relationship between genotypic and phenotypic antibiotic resistance is unclear. We sought to analyze the concordance between the presence of antibiotic resistance (ABR) genes and antibiotic susceptibility results in urine samples collected from symptomatic UTI patients.

Methods: Urine samples were collected from patients presenting with possible UTI to 37 geographically disparate Urology clinics from July 2018 to February 2019. Multiplex polymerase chain reaction (M-PCR) was used to test for 33 different ABR genes. Samples in which at least one organism was identified at a quantity of ≥104 cells per mL, Pooled Antibiotic Susceptibility Testing (P-AST), which involves simultaneously growing all detected bacteria together in the presence of antibiotics and then measuring susceptibility, was performed against 14 different antibiotics. The concordance rate between the ABR genes and the P-AST results was generated for the overall group. The concordance rates for each antibiotic between monomicrobial and polymicrobial infection were compared using chi-square test.

Results: Among the 2,512 patients, bacteria were detected in 1,579. ABR gene genotyping and P-AST analysis was performed for 1,155. ABR genes were detected in 36.3% (419/1155) of specimens. Overall, the presence or absence of ABR genes was 60% concordant with antibiotic susceptibility patterns. Two circumstances accounted for the concordance: ABR gene not present by M-PCR/antibiotic sensitive by P-AST (48.4%) and ABR gene present/antibiotic resistant (11.5%). In the 40% non-concordant cases, 25% were ABR gene not present/antibiotic resistant and 15% were ABR gene present/antibiotic sensitive, **Table 1.** Most antibiotics were associated with similar concordance rates for monomicrobial and polymicrobial infections. However, the concordance rates were significantly lower for polymicrobial for three antibiotics: vancomycin, meropenem, and piperacillin/tazobactam, with absolute differences of 9.3% (p value=0.002), 13.1% (p value<0.0001), and 19.0% (p value = 0.019), respectively.

Conclusion: The concordance rate of the ABR genes as identified by M-PCR and phenotypic resistance as detected by P-AST was 60%. Thus, in 40% of samples, the reliance on the M-PCR antibiotic resistance gene report without the phenotypic data reported by P-AST data may lead to inappropriate treatment.

Table 1. Overall Concordance between Presence of ABR genes by M-PCR and the Antibiotic Susceptibility by P-AST Testing

CONCORDANCE		DISCORDANCE	
ABR detected + Bacteria Resistant based on P-AST	ABR NOT detected + Bacteria Susceptible based on P-AST	ABR detected but Bacteria Susceptible based on P-AST	ABR NOT detected but Bacteria Resistant based on P-AST
11.5%	48.4%	15%	25%
60%		40%	

Funding: Pathnostics